Royal Bank Of Canada Annovis Bio, Inc. Transaction History
Royal Bank Of Canada
- $422 Billion
- Q1 2024
A detailed history of Royal Bank Of Canada transactions in Annovis Bio, Inc. stock. As of the latest transaction made, Royal Bank Of Canada holds 4 shares of ANVS stock, worth $26. This represents 0.0% of its overall portfolio holdings.
Number of Shares
4
Previous 40
90.0%
Holding current value
$26
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding ANVS
# of Institutions
52Shares Held
1.2MCall Options Held
779KPut Options Held
1.77M-
Vanguard Group Inc Valley Forge, PA358KShares$2.34 Million0.0% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA250KShares$1.64 Million0.01% of portfolio
-
Black Rock Inc. New York, NY97.6KShares$639,4690.0% of portfolio
-
Susquehanna International Group, LLP Bala Cynwyd, PA72.6KShares$475,5430.0% of portfolio
-
Geode Capital Management, LLC Boston, MA70.8KShares$463,6810.0% of portfolio
About Annovis Bio, Inc.
- Ticker ANVS
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 8,163,920
- Market Cap $53.5M
- Description
- Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease ...